From ASX release 26 Sept 2018:-Dr Collier said Invion’s licence...

From ASX release 26 Sept 2018:-

Dr Collier said Invion’s licence partner, The Cho Group, will fund the global research and development costs for these programs.Cancer expert Dr Andrew Stephens, the group head of the Ovarian Cancer Biomarkers Research Group at the Hudson Institute, said the PhotosoftTM technology has many potential applications, particularly in cancer types that are already resistant to current chemotherapies.Ovarian cancers have 5-year mortality rate greater than 70%, and patients almost universally develop recurrent, chemo-resistant disease. New therapies are urgently needed.Invion and the Hudson Institute are now ready to start preclinical studies to determine the in vivoeffects of PhotosoftTM Oral and IVX-P02 – not only for the direct treatment of ovarian cancers, but also to induce an anti-tumour immune response which could potentially provide effective protection after treatment.Invion and the Hudson Institute have received ethics approval to start animal studies in the coming weeks, with the first results expected in the next few months.The ability of a photosensitising compound such as PhotosoftTM to kill cells depends upon both the concentration of the compound and how much light energy is delivered to activate it – which in turn is dictated by both the light intensity and duration of exposure.The Invion/Hudson Institute study used the same concentration of PhotosoftTM Oral and IVX-P02, the same activation time and the same intensity of light.“All the parameters are identical. Using IVX-P02, you get a 15-fold increase in cell death,” Dr Stephens said.“That means you can either increase how rapidly you kill the cells, or you can increase the proportion of cells that you kill for the same concentration, in the same amount of time.”IVX-P02 differs from PhotosoftTM Oral in how it is made and synthesised.